Pricing Log in Create free account

Editas Medicine, Inc. (EDIT) vs Rezolute, Inc. (RZLT)

Editas Medicine, Inc. and Rezolute, Inc. are both Biotechnology companies. Editas Medicine, Inc. and Rezolute, Inc. are of similar size ($471.1M and $445.4M). Rezolute, Inc. has the higher net margin (0.00% vs −157.3%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, Rezolute, Inc. leads on 7 and Editas Medicine, Inc. on 5.

Valuation

Metric EDIT RZLT Biotechnology median
P/E n/m n/m 8.56
P/S 6.98 n/m 10.17
P/B 3.12 5.04 2.34
Price to free cash flow n/m n/m 20.42
EV/EBITDA n/m n/m 0.69
EV/Sales 3.17 n/m 9.64
Earnings yield (27.27%) (15.57%) (29.41%)
Free cash flow yield (36.66%) (12.90%) (23.50%)

Profitability

Metric EDIT RZLT Biotechnology median
Gross margin 100.00% 0.00% 65.16%
Operating margin (161.39%) 0.00% 0.00%
Net margin (157.32%) 0.00% 0.00%
Free cash flow margin (255.88%) 0.00% 0.00%
Return on equity (118.82%) (59.04%) (56.66%)
Return on assets (33.02%) (53.82%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric EDIT RZLT Biotechnology median
Revenue growth (TTM) 20.83% — 5.64%
EPS growth (last fiscal year) 37.50% 23.47% 30.08%
Revenue growth, 5-year CAGR (14.89%) — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric EDIT RZLT Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 3.19 9.68 4.72
Net debt to EBITDA 0.94 1.26 0.96

Dividend

Metric EDIT RZLT Biotechnology median
Dividend yield — — 0.08%
Payout ratio — — —

Size

Metric EDIT RZLT Biotechnology median
Market cap 445.38m 471.07m 151.40m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack